Titan Medical Strengthens Patent Portfolio With Issuance of Two Canadian Patents and Allowance of a Japanese Patent
December 13 2017 - 7:30AM
Titan Medical Inc. (“Titan” or the “Company”)
(TSX:TMD) (OTCQB:TITXF), a medical device company focused on the
design, development and commercialization of a robotic surgical
system for application in minimally invasive surgery (“MIS”),
announces the granting of Canadian Patent CA 2973227 and CA
2973235.
These patents are related generally to control
methods for robotic surgical systems, including the provision of
select autonomous control and safety functions that enable optimal
controllability of robotic instruments during use. The methods
describe alignment control of robotic instruments, including
snake-like or multi-articulated instruments as employed in the
SPORT system, which are important for facilitating movement within
the abdomen. Corresponding patent applications are pending in
the U.S. and Europe, and the Company anticipates future issuances
in multiple jurisdictions.
In addition to the issuance of the Canadian
patents, the Company has received an official Decision to Grant
from the Japan Patent Office regarding a pending Japanese patent
application. This application is related to one of the Company’s
previously issued European Patents, EP 2996613, which describes an
articulated tool positioner and system. Upon issuance, which is
expected in 2018, the patent will be the first issued to the
Company outside of North America and Europe.
David McNally, President and CEO of Titan
Medical, said, “Intellectual property is core to our future success
and we are excited to strengthen our proprietary position with the
issuance of the patents in Canada, the fourth and fifth patents
issued this year related to our unique single-port robotic surgical
system. Furthermore, the Decision to Grant received from the Japan
Patent Office will assist in positioning Titan competitively in the
global market for robotic surgical systems. We are encouraged by
the growth of our patent portfolio in 2017, which demonstrates the
novelty of the design of the SPORT system, and we are committed to
continuing to expand Titan’s patent portfolio in 2018 and
beyond.”
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company
focused on research and development through to the planned
commercialization of computer-assisted robotic surgical
technologies for application in minimally invasive surgery. The
Company is currently developing the SPORT Surgical System, a
single-port robotic surgical system. The SPORT Surgical System is
comprised of a surgeon-controlled patient cart that includes a 3D
high definition vision system and multi-articulating instruments
for performing MIS procedures, and a surgeon workstation that
provides the surgeon with an advanced ergonomic interface to the
patient cart and a 3D endoscopic view inside the patient’s body
during MIS procedures. With the SPORT Surgical System, the Company
aims to pursue a broad set of surgical indications, including
general abdominal, gynecologic and urologic procedures.
For more information, please visit the Company’s
website at www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking
statements” which reflect the current expectations of management of
the Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Information Form dated March 31, 2017 (which may be viewed at
www.sedar.com). Should one or more of these risks or uncertainties
materialize, or should assumptions underlying the forward-looking
statements prove incorrect, actual results, performance, or
achievements may vary materially from those expressed or implied by
the forward-looking statements contained in this news release.
These factors should be considered carefully, and prospective
investors should not place undue reliance on the forward-looking
statements. Although the forward-looking statements contained in
the news release are based upon what management currently believes
to be reasonable assumptions, the Company cannot assure prospective
investors that actual results, performance or achievements will be
consistent with these forward-looking statements.
Contacts:
LHA Investor Relations Kim Sutton Golodetz(212)
838-3777kgolodetz@lhai.com orBruce Voss(310)
691-7100bvoss@lhai.com
Titan Medical (TSX:TMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Medical (TSX:TMD)
Historical Stock Chart
From Apr 2023 to Apr 2024